Remove 2018 Remove Immunization Remove Vaccines
article thumbnail

Sanofi and Translate take first mRNA flu vaccine into clinic

pharmaphorum

Sanofi and Translate Bio have started a first clinical trial of an mRNA-based seasonal flu vaccine, adding to the COVID-19 shot already in testing as part of their three-year old collaboration. Sanofi and Translate have been working together since 2018, when they agreed to develop mRNA vaccines for up to five infectious diseases.

Vaccines 114
article thumbnail

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.

Vaccines 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vaxxas announces CEPI partnership to advance needle-free mRNA vaccine patches

pharmaphorum

Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology with preclinical testing of an mRNA vaccine patch. The agreement, worth $4.3 The agreement, worth $4.3

Vaccines 105
article thumbnail

Merck and Moderna’s mRNA cancer vaccine aces its first efficacy trial

pharmaphorum

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna. The vaccine primes the immune system to attack the tumour cells, while Keytruda blocks an immunological ‘brake’ that protects the cancer.

article thumbnail

Japan’s MHLW accepts GSK’s submission for shingles vaccine in adults

Pharmaceutical Technology

The Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted GlaxoSmithKline’s (GSK) regulatory application for recombinant, adjuvanted Zoster vaccine, Shingrix, for preventing shingles (herpes zoster) in at-risk adults of the age 18 years and above.

article thumbnail

How effective is Shingrix?

The Checkup by Singlecare

This rash-causing virus is certainly prevalent, but it’s also avoidable thanks to immunizations like Shingrix. Millions of people have already received at least one dose of this shingles vaccine—but does it actually work? Essentially, once the immune system is familiar with the virus, it will know how to fight it.

article thumbnail

Boost for mRNA as Moderna to acquire OriCiro for $85 million

pharmaphorum

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Biotech Moderna, Inc. and OriCiro Genomics K.K.